Background: To investigate the relationships of hypertension, antihypertensive treatment, and sodium intake on cognitive decline in older women.
Methods: Prospective follow-up of 6,426 cognitively intact women aged 65-79 years enrolled in the Women's Health Initiative Memory Study (WHIMS) with a median follow-up of 9.1 years. Dietary sodium intake was determined by food frequency questionnaires. Hypertension was defined as self-report of current drug therapy for hypertension. Blood pressure (BP) control was assessed by treatment for hypertension and clinic measurement of systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg at baseline. Cognitive functioning was assessed annually by global cognitive screening, neurocognitive, and neuropsychiatric evaluations. Cognitive decline was identified by the incidence of mild cognitive impairment (MCI) or probable dementia (PD). Cox proportional hazards analyses were used to calculate hazard ratios (HRs).
Results: Hypertension was associated with an increased risk for cognitive decline (HR 1.20; 95% confidence interval (CI) 1.04, 1.39; P = 0.02). Among women with antihypertensive medication, those with BP ≥140/90 mm Hg (uncontrolled BP) were at highest risk for developing cognitive decline (HR 1.30; 95% CI 1.05, 1.60) compared to women without treatment and BP <140/90mm Hg (controlled BP). Sodium intake >1,500 mg/day did not alter the risk for cognitive decline in hypertensive women or women with antihypertensive treatment (P for interaction = 0.96 or 0.97).
Conclusions: Women with antihypertensive treatment and uncontrolled BP showed highest risk estimates for developing cognitive decline compared to non-hypertensive women. Sodium intake did not modify the risk for cognitive decline in women with hypertension or receiving antihypertensive medication.
Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT00685009 and NCT00745056.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723668 | PMC |
http://dx.doi.org/10.1093/ajh/hpv081 | DOI Listing |
BMC Pharmacol Toxicol
January 2025
Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, 264100, PR China.
Background: Alzheimer's disease (AD), a hallmark of age-related cognitive decline, is defined by its unique neuropathology. Metabolic dysregulation, particularly involving glutamine (Gln) metabolism, has emerged as a critical but underexplored aspect of AD pathophysiology, representing a significant gap in our current understanding of the disease.
Methods: To investigate the involvement of GlnMgs in AD, we conducted a comprehensive bioinformatic analysis.
BMC Psychiatry
January 2025
School of Mental Health, Bengbu Medical University, Bengbu, Anhui, 233030, China.
Background: Although impaired cognitive control is common during the acute detoxification phase of substance use disorders (SUD) and is considered a major cause of relapse, it remains unclear after prolonged methadone maintenance treatment (MMT). The aim of the present study was to elucidate cognitive control in individuals with heroin use disorder (HUD) after prolonged MMT and its association with previous relapse.
Methods: A total of 63 HUD subjects (41 subjects with previous relapse and 22 non-relapse subjects, mean MMT duration: 12.
Curr Nutr Rep
January 2025
School of Medical, Indigenous and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong NSW, Wollongong, 2522, Australia.
Purpose Of The Review: Clinical trials suggest that dietary anthocyanins may enhance cognitive function. This systematic literature review and meta-analysis aimed to identify the effect of anthocyanin on cognition and mood in adults.
Recent Findings: Using a random-effects model, Hedge's g scores were calculated to estimate the effect size.
Nat Med
January 2025
Centre for Healthy Brain Ageing (CHeBA), School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Effective, scalable dementia prevention interventions are needed to address modifiable risk factors given global burden of dementia and challenges in developing disease-modifying treatments. A single-blind randomized controlled trial assessed an online multidomain lifestyle intervention to prevent cognitive decline over 3 years. Participants were dementia-free community-dwelling Australians aged 55-77 years with modifiable dementia risk factors.
View Article and Find Full Text PDFSci Rep
January 2025
Australian Dysautonomia and Arrhythmia Research Collaborative, Adelaide, SA, Australia.
Cognitive dysfunction is frequently reported in individuals with postural orthostatic tachycardia syndrome (POTS), possibly resulting from reduced cerebral blood flow (CBF). We used brain SPECT, an accessible imaging modality that has not been systematically evaluated in this patient group. Retrospective review of participants from our registry was undertaken to identify those who had a brain SPECT performed for investigation of cognitive dysfunction.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!